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Abstract
We consider a class of optimality criteria and show that each crite-
rion has its unique and equivalent dual within the class. This property
can be used to find a variety of optimal designs, including a class of
compound optimal designs and their relationships. As an example, we
show that one type of D-optimal design provides analytical formula
for a class of compound optimal designs, while its dual, the more
traditional criterion, cannot.
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1 The Placebo-treatment Comparison Prob-
lem
Many experiments involve comparison of several groups receiving diﬀerent
treatments or groups subject to diﬀerent conditions. Such problems are dis-
cussed extensively in the literature; see Fleiss (1986) and, Zhu and Wong
(2000), for example. A common example is in a clinical trial, where patients
are grouped to receive a diﬀerent treatment for each group. Sometimes, the
comparisons among these groups may be of unequal interest to the researcher.
For example, there is a placebo group and there are two other groups, one
receiving aggressive treatments and another receiving less aggressive treat-
ments. The primary objective is to compare the performance of the group
receiving aggressive treatments relative to the placebo group, and the sec-
ondary objective is to compare the performance of the group receiving the
less aggressive treatment relative to the placebo group. The design of the
study should therefore provide higher precision for the primary comparison
than for the secondary comparison.
More generally, consider the situation where there are several objectives
in a clinical trial and we need a design that is deemed adequate for all the I
objectives, (I > 2). Suppose further that the ith objective can be represented
by a functional,Φi, i = 1, ···, I, and this function is convex over the space of all
designs in the design space. The optimal design for the each of the objectives
is the one that minimizes the criterion over all other designs. Designs that
minimize a function of several design criteria are called compound optimal
designs.
In this paper, designs are treated as continuous designs in the sense of
Kiefer’s (1985). The use of continuous designs simpliﬁes the technical prob-
lem and has the advantage that solutions to the problem provide useful guides
to design the study more eﬃciently. We denote an arbitrary design by ξ and
denote the proportion of patients assigned to the ith group by pi, with the
ﬁrst group always designated as the placebo group. For the design problems
at hand, we only need to determine the optimal proportion pi of patients to
be assigned to each of the treatment arms.
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The compound optimal design is a compromise design that balances the
various competitive objectives in the trial. When the diﬀerent levels of inter-
est in each of the objectives are speciﬁed by the researcher through the values
of the weights λ’s, the compound optimal deisgn is found by minimizing the
functional
Φ (ξ | λ) =
I∑
i=1
λiΦi (ξ) ,
where 0 ≤ λi ≤ 1 and ∑Ii=1 λi = 1. Here, each of the weights λi is user-
selected, with more important objectives being given a larger value for the
weight. The above functional is a convex combination of convex functions
and so it is also convex. Consequently, the optimal design can be found using
technqiues similar to ﬁnding an optimal design under a single objective.
To ﬁx ideas, consider the treatment-placebo comparison problem in a
clinical trial with one placebo and several treatments. The model is
yij = βi + εij,
where βi represents the eﬀect of treatment i, i = 1, · · ·, K, and j is the
patient indicator, j = 1, · · ·, N . We assume that εij represents the normally
distributed error term with mean zero and constant variance, and the error
terms are independently distributed of one another. Our objective i is to
estimate (βi+1 − β1) as precisely as possible, i = 1, · · ·, K − 1, assuming
treatment 1 denotes the placebo group.
Following convention, we measure the worth of a design ξ by its expected
Fisher information matrix, M(ξ) (Atkinson and Donev, 1992, p.95). Under
our setup, it is straightforward to verify that such matrices are always di-
agonal. If we let ATi =
(
1 0 · · · −1 0 · · · 0
)
, where (−1) is in the
(i + 1) th position, a direct calculation shows
Φi (ξ) = ln
∣∣∣ATi M−1 (ξ)Ai∣∣∣ = ln
(
N
n1
+
N
ni+1
)
= ln
(
1
p1
+
1
pi+1
)
.
Here N is the total sample size, ni is the sample size in the ith group and
ni/N = pi is the proportion of patients assigned to the ith group, i = 1, · ·
·, K. In practice, N is pre-determined ; for example, in clinical trials, the
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researcher should have prior information on the number of patients he or she
can realistically recruit into the trial during the given time frame.
When there are diﬀerent interests in each of the comparisons, we may use
diﬀerent weights for these objectives. For given values of the weights, λ’s, let
Φ (ξ | λ) = ∑K−1i=1 λiΦi (ξ), where 0 < λi < 1, ∀i, and
Υ
(
p, ρ
)
= Φ(ξ | λ) + ρ
(
K∑
i=1
pi − 1
)
.
The optimal design (i.e. the optimal values of p∗i ) can be found by solving
the following set of equations:
∂Υ
∂p1
=
1
p1
·
K−1∑
i=1
λi · pi+1
p1 + pi+1
+ ρ = 0;
∂Υ
∂pi+1
=
1
pi+1
· λi · p1
p1 + pi+1
+ ρ = 0, i = 1, · · ·, K − 1;
and
∂Υ
∂ρ
=
K∑
i=1
pi − 1 = 0.
Further algebra shows ρ = −1 and the above system of equations reduces to
K−1∑
i=1
√
p21 + 4λip1 = 2 + (K − 3) p1(1)
and
pi+1 =
−p1 +
√
p21 + 4λip1
2
, i = 1, · · ·, K − 1.(2)
The general analytic solution is not available, but it is interesting to note
that when all comparisons are of equal importance, i.e. λi = 1/ (K − 1),
i = 1, · · ·, K − 1, we have
p∗1 =
1
1 +
√
K − 1(3)
and
p∗i =
1
K − 1 +√K − 1 =
1√
K − 1p
∗
1, i = 2, · · ·, K.(4)
This means that when we are equally interested in comparing all (K − 1)
pairs of placebo and treatment, we should allocate equal number of patients
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to each of the (K − 1) treatments and √K − 1 times this number of patients
to the placebo. The above result is thus a generalization of the well known
result given in Fleiss (1986, page 96) for comparing several treatments versus
a placebo and there is equal interest in all the comparisons.
2 Another D-optimality Type Criterion
It is instructive to consider an alternative D-optimality criterion given by
Φ˜ (ξ) =
∣∣∣ATM−1 (ξ)A∣∣∣ ,
where A is a user-selected semi-positive matrix. The choice for the matrix A
depends on the objective of the study. As in D-optimality, we seek a design
to minimize this criterion over all designs. Let Ai be as before, and note that
we now have
Φ˜i (ξ) =
∣∣∣ATi M−1 (ξ)Ai∣∣∣ = Nn1 +
N
ni+1
=
1
p1
+
1
pi+1
,
where ni/N = pi, i = 1, · · ·, K. Let Φ˜ (ξ | λ) = ∑K−1i=1 λiΦ˜i (ξ), where 0 <
λi < 1, ∀i, and we have
Υ
(
p, ρ
)
= Φ˜ (ξ | λ) + ρ
(
K∑
i=1
pi − 1
)
=
K−1∑
i=1
λi
(
1
p1
+
1
pi+1
)
+ ρ
(
K∑
i=1
pi − 1
)
=
1
p1
+
K−1∑
i=1
λi
1
pi+1
+ ρ
(
K∑
i=1
pi − 1
)
.
The compound optimal design can be found by solving the following set of
equations:
∂Υ
∂p1
= − 1
p21
+ ρ = 0;
∂Υ
∂pi+1
= − λi
p2i+1
+ ρ = 0, i = 1, · · ·, K − 1;
and
∂Υ
∂ρ
=
K∑
i=1
pi − 1 = 0.
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Further algebra shows that the above system of equations reduces to
pi+1 =
√
λip1, i = 1, · · ·, K − 1
and
K∑
i=1
pi − 1 = 0.
The general analytic solution is readily obtained as
p1 =
1
1 +
∑K−1
i=1
√
λi
;
pi+1 =
√
λi
1 +
∑K−1
i=1
√
λi
, i = 1, · · ·, K − 1.
It is interesting to note that when we are equally interested in all the
pairwise comparisons, we set λi = 1/ (K − 1), i = 1, · · ·, K − 1, and obtain
the same design as before ,i.e.
p∗1 =
1
1 +
√
K − 1(5)
and
p∗i =
1√
K − 1p
∗
1, i = 2, · · ·, K.
An explanation of this property from a theoretical point of view is given in
Corollary 3 of Section 5.
Table 1 shows the two types of D-optimal designs when there are K = 4
comparison groups for selected choice of weights. When there is unequal
interest in each of the comparisons, the two types of D-optimal designs are
diﬀerent; otherwise, they coincide as the theory just showed. Under both
criteria, the D-optimal design assigns more patients to the group deemed
more important than the other groups. For instance, the ﬁrst row of Table
1 shows the comparison between the fourth group and the placebo group is
deemed the most important with a weight of 0.7. The proportion of patients
assigned to group 4 is 36.7%, which is the highest among the groups 2, 3
and 4. We also note that in all cases, the placebo group receives the most
patients. This makes sense because this is the group most involved in all the
comparisons.
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Table 1: Two types of D-optimal designs for 3 treatment groups and diﬀerent
weights are used to compare their eﬀects relative to the placebo group (group
1). The proportions in parentheses are those obtained using the criterion
without the log.
λ1 λ2 λ3 p1 p2 p3 p4
0.1 0.2 0.7 0.404 (0.385) 0.083 (0.122) 0.147 (0.172) 0.367 (0.322)
1/3 1/3 1/3 0.366 (0.366) 0.211 (0.211) 0.211 (0.211) 0.211 (0.211)
0.1 0.5 0.4 0.386 (0.377) 0.082 (0.119) 0.287 (0.266) 0.245 (0.238)
3 Convexity of the Two D-optimality Crite-
ria
Atkinson and Donev (1992, pg. 96) pointed out that the reason for adopting
the D-optimality criterion Φ (ξ) = ln
∣∣∣ATM−1 (ξ)A∣∣∣ over the criterion Φ (ξ) =∣∣∣ATM−1 (ξ)A∣∣∣ is that “taking the logarithm of the determinant leads to
minimization of a convex function, so that any minimum found will certainly
be global rather than local.” The convexity referred to here is the criterion
function as a function of the information matrix M (ξ). From Atkinson and
Donev (1992) it follows easily that the criterion Φ (ξ) = ln
∣∣∣ATM−1 (ξ)A∣∣∣ is
strictly convex in p.
We claim that for the above placebo-treatment comparison problem the
property of strict convexity is also satisﬁed for the criterion Φ˜ (ξ) =
∣∣∣ATM−1 (ξ)A∣∣∣,
and therefore, minimizing the function Φ or Φ˜ with respect to p would provide
us with the global minimum in either case.
To verify our claim, we recall that a two times continuously diﬀerentiable
function f is strictly convex on Ω if and only if ∇2f (x) is positive deﬁnite
for all x ∈ Ω (Hiriart-Urruty and Lemare´chal, 1993). It is easy to see that if
we take f(p1, p2, · · · , pk) = ∑K−1i=1 λi(1/p1 + 1/pi+1), then
(f)T =
(
− 1
p21
,−λ2
p22
, · · · ,−λK−1
p2K−1
,
)
and
∇2f =


2
p31
0 · · · 0
0 λ2
p32
· · · 0
...
...
. . . 0
0 0 0 λK−1
p3K−1


.
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Therefore ∇2f is positive deﬁnite for all p. With the convexity issue resolved,
we are now ready to present a general theorem that is useful for understanding
the relationship between the above two classes of compound optimal designs.
4 A Class of Optimality Criteria
Consider optimality criteria of the form
{
K−1∑
i=1
λi|AiM−1(ξ)Ai|−p
}1/p
= Φp,λ(ξ)
where λ = (λ1, . . . , λk−1) denotes a weight vector and p ∈ [−∞, 1].
The cases p = −1 and p = 0,−∞ are of particular interest because they
give
Φ−1,λ(ξ) = {
K−1∑
i=1
λi|ATi M−1(ξ)Ai|}−1
Φ0,λ(ξ) =
K−1∏
i=1
|ATi M−1(ξ)Ai|−λi = limp→0Φp,λ(ξ)
Φ−∞,λ(ξ) =
K−1
min
i=1
(ATi M
−1(ξ)Ai)−1 = lim
p→−∞Φp,λ(ξ).
Note that the cases p = 0 and p = 1 correspond to the criteria Φ and
Φ˜ discussed in Section 2 and 3. We now provide a result that shows opti-
mal designs constructed under this class of optimality criteria have a dual
relationship. Speciﬁcally, every optimal design found with respect to a crite-
rion in this class of optimality criteria is also simultaneously optimal under
another criterion of the class provided the weight vector is properly chosen.
Theorem 1: Assume that p ∈ (−∞, 1].
(1) Let ξ∗ denote a design that maximizes Φp,λ for the weight vector λ =
(λ1, . . . , λK−1). Then for any q ∈ (−∞, 1] the design ξ∗ also maximizes
Φq,µ, where the weight vector µ = (µ1, . . . , µK−1) is given by
µj =
λj(
1
p1
+ 1
pj+1
)q−p∑K−1
i=1 λi(
1
p1
+ 1
pi+1
)q−p
j = 1, . . . , K − 1
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and pi = ni/N denotes the proportion of total observations allocated by
the design ξ∗ to treatment i(i = 1, . . . , K − 1).
(2) If ξ∗ maximizes Φ−1,λ for the weight vector λ = (λ1, . . . , λK−1) then ξ∗
maximizes Φ0,µ for the weight vector µ = (µ1, . . . , µK−1), where
µj =
λj +
√
λj
1 +
∑K−1
i=1
√
λi
j = 1, . . . , K − 1.
Proof. Part (1) follow immediately from Theorem 2.4 in Dette (1993)
and a straight forward calculation of the information matrix M(ξ∗) [see Zhu
and Wong (2000)]. For part (2) we note that the optimal weights for max-
imizing Φ−1,λ can be obtained directly using Lagrange’s multipliers. The
optimal weights for the placebo group and the treatment groups are respec-
tively given by
p1 =
1
1 +
∑K−1
i=1
√
λi
and
pi+1 =
√
λi
1 +
∑K−1
i=1
√
λi
i = 1, . . . , K − 1.
This implies
1
pi
+
1
pi+1
= (1 +
K−1∑
i=1
√
λi)(1 +
1√
λi
)
and the assertion now follows from part (1) for q = 0 and p = −1.
The next result concerns a maximin type of criterion. Maximin or mini-
max design criteria are popular and have been studied in the literature since
1950 ; some recent work includes Wong (1992) and Dette (1993). This design
criterion is particularly useful if we wish to design a study to minimize the
maximal variance of all the estimated contrasts. This criterion is also used
in situations where it is roughly known in advance that a set of contrasts
may be of interest, but which one of the contrasts will be of ultimate interest
is not known until the study is completed. Clearly, the maximization of this
criterion
Φ−∞(ξ) =
K−1
min
i=1
(ATi M
−1(ξ)Ai)−1
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is equivalent to minimizing
1/Φ−∞(ξ) =
K−1
max
i=1
(ATi M
−1(ξ)Ai),
i.e. by maximizing Φ−∞, we minimize the worst possible variance.
Theorem 2. Suppose we wish to ﬁnd a design that maximizes Φ−∞.
The optimal proportion of patients assigned to the placebo group and the
treatment groups are respectively given by
p∗1 =
1
1 +
√
K − 1
p∗i+1 =
1√
K − 1p
∗
1 i = 1, . . . ,= K − 1.
Proof. The equivalence theorem for the maximin criterion can be derived
as follows. First, deﬁne the set
N (ξ∗) = {j ∈ {1, . . . , K − 1} | (ATj M−1(ξ∗)Aj)−1 = Φ−∞(ξ∗)}.
Using standard maximin arguments [see Pukelsheim (1993)], it can be shown
that ξ∗ maximizes Φ−∞ if and only if there exists nonnegative weights α1, . . . , αK−1
such that
K−1∑
i=1
αi = 1
αi = 0 if i ∈ N (ξ∗)
and the inequality
K−1∑
=1
α
(AT M
−1(ξ)x)T
AT M
−1(ξ)A
≤ 1
holds for all x ∈ {(1, 0, . . . , 0)T , (0, 1, 0, . . . , 0)T , . . . , (0, . . . , 0, 1)T}.
The assertion now follows by a straightforward calculation using the de-
sign speciﬁed in Theorem 2 and the weights αi = 1/(K − 1). We note that
for this particular choice, N (ξ∗) = {1, . . . , K − 1}.
Corollary 3: For any p ∈ [−∞, 1] the design specified by Theorem 2
is Φp,λ∗ optimal, where λ
∗ denotes the uniform weight vector, i.e. λ∗ =
{ 1
K−1 , . . .
1
K−1}.
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Proof. The proof has been established for p = −∞ [Theorem 2] p = 0
and p = −1 [Zhu and Wong (2000)]. The remaining cases follow from the
ﬁrst part of Theorem 2 [p = 0] for any q ∈ (−∞, 1].
5 Summary
It is generally diﬃcult to construct an optimal design when there are sev-
eral competing objectives in the study. Analytical solution of the optimal
design is hardly available. We show in this paper that a D-optimality type
of criterion always yields closed form formulae for the optimal designs in the
placebo-treatment types of problems. The design criterion can also be use-
fully embedded into a broader class of criteria and dual relationships among
optimal designs are presented. This is especially useful because optimal de-
sign under one criterion can now be directly deduced from optimal design
found under another optimality criterion. In particular, we can easily ﬁnd
optimal design for a a more complicated criterion using an optimal design
found under a simpler criterion such as when p = 0. We also consider the
special role of the minimax criterion and show that the minimax optimal
designs are also optimal with respect to all criteria in the given class.
The choice of an optimality criterion or a set of criteria to work with is
problem dependent and usually the researcher has a couple of options. For
instance, if interest is centered on estimation, A or D-optimality criteria is
frequently used. In practice, it is advisable that the researcher ﬁnds sev-
eral reasonable optimal desgins for his or her problems and compare their
sensitivities to model assumptions and robustness properties under a range
of criteria. Our paper proposes a class of optimal designs for comparing
the placebo group and several treatment groups using a class of optimality
crtieria and show that the optimal design has several desirable properties.
First, the placebo group always has the highest proportion of patients; this
is reasonable because the placebo group is the most used group in the set
of comparisons. Second, the treatment groups that are heavier weighted
require larger sample sizes, and third, the optimal design can be analyti-
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cally described. It should also be noted that because of the ﬁrst and second
properties, greater precision is ensured for the more important comparisons.
Acknowledgments. The research of Wong is partially supported by a
NIH research grant R29 AR44177-01A1. The work of H. Dette was sup-
ported by the Deutsche Forschungsgemeinschaft (DE 502/14-1 and SFB 475,
Komplexita¨tsreduktion in multivariaten Datenstrukturen, Teilprojekt A2).
References
Atkinson, A. C. and Donev, A. N. (1992) Optimum Experimental Designs.
Clarendon press, Oxford.
Dette, H. (1993). A New Interpretation of Optimality for E-optimal
Designs in Linear Regression Models. Metrika 40, 37-50.
Fleiss, J. L. (1986). The Design and Analysis of Clinical Experiments.
Wiley, New York.
Hiriart-Urruty and Lemare´chal (1993). Convex Analysis. Springer-Verlag.
Kiefer, J. (1985). Jack Carl Kiefer Collected Papers III: Design of Exper-
iments. Springer-Verlag. New York.
Pukelsheim, F. (1993). Optimal Design of Experiments. Wiley, New
York.
Wong, W. K. (1992). A Uniﬁed Approach to the Construction of Mini-
Max Designs. Biometrika, 79(3), 611-620.
Zhu, W. and Wong, W. K. (2000). Optimal Treatment Allocation in
Comparative Biomedical Studies. Statistics in Medicine, 19(5), 639-648.
12
